4528 Stock Overview
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,290.50 |
| 52 Week High | JP¥2,966.50 |
| 52 Week Low | JP¥2,238.00 |
| Beta | 0.18 |
| 1 Month Change | -9.23% |
| 3 Month Change | -13.07% |
| 1 Year Change | -16.01% |
| 3 Year Change | -17.31% |
| 5 Year Change | 10.15% |
| Change since IPO | 86.22% |
Recent News & Updates
Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00
Mar 04
Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?
Feb 27Shareholder Returns
| 4528 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -2.8% | -3.0% | -4.7% |
| 1Y | -16.0% | 2.7% | 26.3% |
Return vs Industry: 4528 underperformed the JP Pharmaceuticals industry which returned 2.7% over the past year.
Return vs Market: 4528 underperformed the JP Market which returned 26.3% over the past year.
Price Volatility
| 4528 volatility | |
|---|---|
| 4528 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4528 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4528's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 3,761 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| 4528 fundamental statistics | |
|---|---|
| Market cap | JP¥1.08t |
| Earnings (TTM) | JP¥127.61b |
| Revenue (TTM) | JP¥498.07b |
8.4x
P/E Ratio2.2x
P/S RatioIs 4528 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4528 income statement (TTM) | |
|---|---|
| Revenue | JP¥498.07b |
| Cost of Revenue | JP¥121.74b |
| Gross Profit | JP¥376.33b |
| Other Expenses | JP¥248.72b |
| Earnings | JP¥127.61b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 271.68 |
| Gross Margin | 75.56% |
| Net Profit Margin | 25.62% |
| Debt/Equity Ratio | 0% |
How did 4528 perform over the long term?
See historical performance and comparison